Newsletter February 2024
EPO Berlin-Buch will receive funding from the ProFIT program of the Investitionsbank Berlin and the European Union (EFRE, Europäischer Fonds für regionale Entwicklung) for participating on a collaborative research project on novel T-cell therapies. This joint project was initiated by the biotech companies HS Diagnomics and TheryCell together with partners from Charités Clinic of Hematology, Oncology & Cancer Immunology and Institute of Pathology.
The project's focus is on the development of T cell receptor (TCR)-T therapies for solid tumors, specifically targeting Pancreatic Ductal Adenocarcinoma, Colorectal Carcinoma, and Breast Cancer. The collaborative effort aims to identify therapeutic TCR’s from patients, ultimately leading to the establishment of both personalized and off-the-shelf TCR-T cell therapies.
EPO Berlin-Buch contributes with its extensive expertise in preclinical evaluation of novel cell and immune therapies for cancer patients. This multi-faceted collaboration holds promise for advancing research and contributing to the development of innovative and effective treatment options for individuals with these challenging types of cancers.